Kerrie B Spencer

8551984, Oct 8, 2013

Dec 15, 2010

12/968608

Michael D. Altman - Needham MA, US
Brian M. Andresen - Sharon MA, US
Kenneth L. Arrington - Revere MA, US
Jason Burch - Westmount, CA
Kaleen Konrad Childers - Newton MA, US
Bernard Cote - Notre-Dame-de-l'lle-Perrot, CA
Maria Emilia Di Francesco - Brookline MA, US
Anthony Donofrio - Cambridge MA, US
Kristina Dupont-Gaudet - Vaudreuil-Dorion, CA
John Michael Ellis - Needham MA, US
Christian Fischer - Natick MA, US
Daniel Guay - Lachine, CA
David Joseph Guerin - Natick MA, US
Andrew M. Haidle - Cambridge MA, US
Solomon Kattar - Arlington MA, US
Sandra Lee Knowles - Boston MA, US
Chaomin Li - Boston MA, US
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Brookline MA, US
Alan B. Northrup - Reading MA, US
Brendan M. O'Boyle - Boston MA, US
Ryan D. Otte - Natick MA, US
Michael H. Reutershan - Brookline MA, US
Eric Romeo - Alliston MA, US
Adam J. Schell - Newton MA, US
Tony Siu - Brookline MA, US
Kerrie B. Spencer - Woonsocket RI, US
Brandon M. Taoka - Brookline MA, US
B. Wesley Trotter - Newton Highland MA, US
Hua Zhou - Acton MA, US

Merck Sharp & Dohme Corp. - Rahway NJ
Merck Canada Inc. - Kirkland, Quebec

C07D 417/12
A61K 31/497

51421208, 51421706, 5142358, 51425202, 51425219, 514275, 540524, 540601, 544122, 544238, 544295, 544296, 544331

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

20100256097, Oct 7, 2010

Jun 16, 2008

12/665045

Michael Altman - Cambridge MA, US
Matthew Christopher - Wallingford CT, US
Jonathan B. Grimm - Newton MA, US
Andrew Haidle - Cambridge MA, US
Kaleen Konrad - Newton MA, US
Jongwon Lim - Lexington MA, US
Rachel N. MacCoss - Brookline MA, US
Michelle Machacek - Brookline MA, US
Ekundayo Osimboni - Ashland MA, US
Ryan D. Otte - Natick MA, US
Tony Siu - Brookline MA, US
Kerrie Spencer - Woonsocket RI, US
Brandon Taoka - Allston MA, US
Paul Tempest - Brookline MA, US
Kevin Wilson - West Newton MA, US
Hyan Chong Woo - Brookline MA, US
Jonathan Young - Southborough MA, US
Anna Zabierek - Salem MA, US

A61K 31/675
C07D 409/14
A61K 31/4439
A61K 31/4436
C07D 413/14
A61K 31/5377
C07D 409/12
A61K 31/501
C07F 9/28
C07D 417/14
A61K 31/541

514 89, 5462754, 514341, 5462804, 514336, 544122, 5142362, 544107, 5142322, 544238, 51425201, 5142102, 546 22, 544 582, 5142278

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

20120277192, Nov 1, 2012

Dec 15, 2010

13/516455

Michael D. Altman - Needham MA, US
Brian M. Andresen - Sharon MA, US
Kenneth L. Arrington - Revere MA, US
Sathesh Bhat - Dollard-des-Ormeaux, CA
Jason Burch - Redwood City CA, US
Kaleen Konrad Childers - Newton MA, US
Bernard Cote - Notre-Dame-de-I'Ile-Perrot, CA
Maria Emilia Di Francesco - Houston TX, US
Anthony Donofrio - Cambridge MA, US
Kristina Dupont-Gaudet - Vaudreuil-Dorion, CA
John Michael Ellis - Needham MA, US
Christian Fischer - Natick MA, US
Jean-Francois Fournier - Montreal, CA
Jacques Yves Gauthier - Laval, CA
Jonathan Grimm - Asburn VA, US
Daniel Guay - Lachine, CA
David Joseph Guerin - Natick MA, US
Andrew M. Haidle - Cambridge MA, US
Solomon Kattar - Arlington MA, US
Sandra Lee Knowles - Princeton NJ, US
Chaomin Li - Boston MA, US
Jongwon Lim - Lexintong MA, US
Michelle R. Machacek - Brookline MA, US
Matthew L. Maddess - Boston MA, US
Alan B. Northrup - Reading MA, US
Brendan M. O'Boyle - Boston MA, US
Ryan D. Otte - Natick MA, US
Alessia Petrocchi - Houston TX, US
Michael H. Reutershan - Brookline MA, US
Joel S. Robichaud - Dollar-des-Ormeaux, CA
Eric Romeo - Allston MA, US
Adam J. Schell - Decatur GA, US
Tony Siu - Brookline MA, US
Kerrie B. Spencer - Woonsocket RI, US
Brandon M. Taoka - Hoboken NJ, US
B. Wesley Trotter - Newton Highlands MA, US
Hyun Chong Woo - Natick MA, US
Hua Zhou - Acton MA, US

A61K 31/506
A61K 31/55
A61K 31/554
A61K 31/551
A61P 35/00
C07D 417/14
C07F 9/6539
C07D 417/12
A61P 19/02
A61P 11/06
A61K 31/675
A61K 31/5377

514 86, 5142102, 51421202, 51421208, 514218, 5142358, 514249, 514275, 540488, 540492, 540524, 544123, 544243, 544321

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

20120309735, Dec 6, 2012

Dec 16, 2010

13/515941

Michael D. Altman - Needham MA, US
Kenneth L. Arrington - Revere MA, US
Jason Burch - Redwood City CA, US
Bernard Cote - Notre-Dame-de-I'lle-Perrot, CA
Jean-Francois Fournier - Juan les Pins, FR
Jacques Yves Gauthier - Laval des Rapides, CA
Solomon Kattar - Arlington MA, US
Sandra Lee Knowles - Princeton NJ, US
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Brookline MA, US
Alan B. Northrup - Reading MA, US
Michael H. Reutershan - Brookline MA, US
Joel S. Robichaud - Dollard des Ormeaux, CA
Adam J. Schell - Decatur GA, US
Kerrie B. Spencer - Woonsocket RI, US

A61K 31/506
C07D 417/12
C07D 417/14
C07D 471/04
A61P 19/02
A61K 31/551
A61P 11/06
A61P 11/00
A61P 29/00
C07D 471/10
A61K 31/5377

5142102, 544230, 514275, 544331, 544296, 544295, 51425505, 544122, 5142358, 51425219, 540492, 514218, 514249, 540575

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

20220363656, Nov 17, 2022

Jun 10, 2021

17/343994

- Rahway NJ, US
Jongwon Lim - Lexington MA, US
Satyanarayana Tummanapalli - Hyderabad, IN
Phieng Siliphaivanh - Newton MA, US
Kerrie Spencer - Woonsocket RI, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 311/22
C07D 405/06
C07D 405/14
C07D 409/06
C07D 413/06
C07D 417/06

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

20190382363, Dec 19, 2019

Nov 28, 2016

15/768880

- Rahway NJ, US
Jongwon Lim - Lexington MA, US
Satyanarayana Tummanapalli - Hyderabad, IN
Phieng Siliphaivanh - Newton MA, US
Kerrie Spencer - Woonsocket RI, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 311/22
C07D 409/06
C07D 405/06
C07D 417/06
C07D 413/06
C07D 405/14

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

20180312499, Nov 1, 2018

Nov 28, 2016

15/769079

- Rahway NJ, US
Satyanarayana Tummanapalli - Hyderabad, IN
Phieng Siliphaivanh - Newton MA, US
Kerrie Spencer - Woonsocket RI, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 417/14
C07D 405/14
A61P 3/10

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

20180305342, Oct 25, 2018

Nov 28, 2016

15/767371

Yongxin HAN - Boston MA, US
Jongwon LIM - Boston MA, US
Phieng SILIPHAIVANH - Boston MA, US
Kerrie SPENCER - Boston MA, US
Satyanarayana TUMMANAPALLI - Albany NY, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 405/06
C07D 311/22
C07D 417/06
C07D 413/06

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension. Non-alcoholic fatty liver disease/nonalcoholic steatoepatitis metabolic syndrome, atherosclerosis, and cancer.